Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

Bibliographic Details
Main Authors:	Ying Chen, Rui Li, Yuqi Zhu, Sixia Zhong, Jinjun Qian, Dongqing Yang, Artur Jurczyszyn, Meral Beksac, Chunyan Gu, Ye Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Oncology
Subjects:	dihydroartemisinin artemisinin multiple myeloma dexamethasone drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.736373/full

Similar Items

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
by: Ying Chen, et al.
Published: (2020-05-01)

Efficacy and safety of artemisinin-naphthoquine <it>versus</it> dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia
by: Tjitra Emiliana, et al.
Published: (2012-06-01)

Efficacy of Artemisinin-Naphtoquine and Dihydroartemisinin-Piperaquine for uncomplicated malaria patient at primary health care
by: Hadjar Siswantoro, et al.
Published: (2015-01-01)

Efficacy of Artemisinin-Naphtoquine and Dihydroartemisinin-Piperaquine for uncomplicated malaria patient at primary health care
by: Hadjar Siswantoro, et al.
Published: (2015-01-01)

Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam
by: Bui Quang Phuc, et al.
Published: (2017-04-01)

Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models
by: Laura C. Gunder, et al.
Published: (2022-07-01)

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
by: Rui Li, et al.
Published: (2022-10-01)

Therapeutic potential of artemisinin and its derivatives in managing kidney diseases
by: Qi Jin, et al.
Published: (2023-02-01)

Design, Synthesis and Anti-Lung Cancer Evaluation of 1, 2, 3-Triazole Tethered Dihydroartemisinin-Isatin Hybrids
by: Haodong Hou, et al.
Published: (2021-12-01)

Artemisinin anti-malarial drugs in China
by: Zongru Guo
Published: (2016-03-01)

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma
by: Li Du, et al.
Published: (2022-01-01)

LC-MS/TOF Characterization and Stability Study of Artesunate in Different Solvent Systems
by: Kogila Oke, et al.
Published: (2022-08-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated <it>Plasmodium falciparum</it> malaria in India
by: Gargano Nicola, et al.
Published: (2012-07-01)

An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat
by: Zhu Fanping, et al.
Published: (2012-11-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Design, Synthesis, and Mechanism of Dihydroartemisinin–Coumarin Hybrids as Potential Anti-Neuroinflammatory Agents
by: Haonan Yu, et al.
Published: (2019-04-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer
by: Fei Zhang, et al.
Published: (2017-05-01)

Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy
by: Yun Lu, et al.
Published: (2020-01-01)

Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
by: Frederico Luiz Dulley, et al.

Dihydroartemisinin induces pyroptosis and regulates apoptosis-associated speck-like protein methylation in prostate cancer cells
by: ZHOU Sijie, et al.
Published: (2022-07-01)

Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates
by: Elena Marchesi, et al.
Published: (2023-08-01)

The Real Cytotoxic Effect of Artemisinins on Colon Cancer Cells in a Physiological Cell Culture Setting. How Composition of the Culture Medium Biases Experimental Findings
by: Dagmara Otto-Ślusarczyk, et al.
Published: (2021-09-01)

New Uses for Old Drugs: The Tale of Artemisinin Derivatives in the Elimination of Schistosomiasis Japonica in China
by: Yi-Xin Liu, et al.
Published: (2014-09-01)

Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review
by: O. Oey, et al.
Published: (2022-11-01)

Dihydroartemisinin regulates apoptosis, migration, and invasion of ovarian cancer cells via mediating RECK
by: Jingfei Zheng, et al.
Published: (2021-06-01)

Efficacy and safety of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials
by: Dawit Getachew Assefa, et al.
Published: (2021-04-01)

Choreoathetosis – an unusual adverse effect of dihydroartemisinin-piperaquine: a case report
by: Benjamin Momo Kadia, et al.
Published: (2017-12-01)

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
by: Reza Safaee, et al.
Published: (2012-07-01)

Nanostructured Dihydroartemisinin Plus Epirubicin Liposomes Enhance Treatment Efficacy of Breast Cancer by Inducing Autophagy and Apoptosis
by: Ying-Jie Hu, et al.
Published: (2018-10-01)

Dihydroartemisinin reduces lung injury in rats with hemorrhagic shock
by: YANG Ning, WANG Da-wei, ZHAO Ya-bin, CHANG Dong-ge, HE Ying-ying
Published: (2021-09-01)

Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves’ Ophthalmopathy by Targeting Orbital Fibroblasts
by: Shenglan Yang, et al.
Published: (2022-05-01)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
by: María Victoria Mateos, et al.
Published: (2023-02-01)

Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells
by: Jun Luo, et al.
Published: (2021-06-01)

Dihydroartemisinin alleviates deoxynivalenol induced liver apoptosis and inflammation in piglets
by: Jibo Li, et al.
Published: (2022-08-01)

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Severe Embryotoxicity of Artemisinin Derivatives in Experimental Animals, but Possibly Safe in Pregnant Women
by: Qigui Li, et al.
Published: (2009-12-01)

Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone
by: Daisuke Taniguchi, et al.
Published: (2009-07-01)